

## DAFTAR PUSTAKA

- Aral, S. O. and Douglas, J. M. (eds) (2007) *Behavioral Interventions for Prevention and Control of Sexually Transmitted Diseases*. Springer US. doi: 10.1007/978-0-387-48740-3.
- Bahia, L. R. *et al.* (2012) 'Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system', *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, 38(5), pp. 595–605. doi: 10.1590/s1677-55382012000500003.
- Barkin, J. *et al.* (2003) 'Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride', *European Urology*, 44(4), pp. 461–466. doi: 10.1016/s0302-2838(03)00367-1.
- Bjerkklund Johansen, T. E., Baker, T. M. and Black, L. K. (2012) 'Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial', *BJU international*, 109(5), pp. 731–738. doi: 10.1111/j.1464-410X.2011.10511.x.
- DerSarkissian, M. *et al.* (2016) 'Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States', *Journal of Managed Care & Specialty Pharmacy*, 22(10), pp. 1204–1214. doi: 10.18553/jmcp.2016.22.10.1204.
- Direktorat Jenderal Bina Kefarmasian dan alat Kesehatan (2013) *Pedoman Penerapan Kajian Farmakoekonomi*. Kemenkes Republik Indonesia.
- Drummond, M. F. *et al.* (2015) *Methods for the Economic Evaluation of Health Care Programmes*. Fourth Edition. Oxford, New York: Oxford University Press.
- Eisenberg, J. *et al.* (2002) 'Pharmacoeconomics: Economic Evaluation of Pharmaceuticals', in, pp. 573–601. doi: 10.1002/0470842555.ch35.
- Erman, A. *et al.* (2018) 'Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis', *BJU international*, 122(5), pp. 879–888. doi: 10.1111/bju.14520.
- European Association of Urology (2017) *EAU Guidelines: Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)*. Available at:

<https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>  
(Accessed: 10 July 2021).

- Geitona, M. *et al.* (2014) 'Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting', *BMC urology*, 14, p. 78. doi: 10.1186/1471-2490-14-78.
- Guevara-Cuellar, C. A. *et al.* (2018) 'Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience', *Value in Health Regional Issues*, 17, pp. 174–182. doi: 10.1016/j.vhri.2018.09.004.
- Ikatan Ahli Urologi Indonesia (2017) *Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia/BPH)*. Jakarta: Ikatan Ahli Urologi Indonesia.
- Kementerian Kesehatan RI Komite Penilaian Teknologi Kesehatan (2017) *Buku Panduan Penilaian Teknologi Kesehatan*. Jakarta: Kementerian Kesehatan RI.
- Kim, H. W. *et al.* (2011) 'Effect of Shifting from Combination Therapy to Monotherapy of  $\alpha$ -Blockers or  $5\alpha$ -Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia', *Korean Journal of Urology*, 52(10), pp. 681–686. doi: 10.4111/kju.2011.52.10.681.
- Lee, S. W. H., Chan, E. M. C. and Lai, Y. K. (2017) 'The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis', *Scientific Reports*, 7(1), p. 7984. doi: 10.1038/s41598-017-06628-8.
- Manaf, R. *et al.* (2017) 'Designing and Conducting Cost-Effectiveness Analysis Studies in Healthcare', *International Journal of Public Health and Clinical Sciences*, 4.
- McAninch, J. W. and Lue, T. F. (2012) *Smith and Tanagho's General Urology*. 18th Edition. New York: McGraw-Hill Medical.
- Orion (1997) *Pharmacoeconomics Primer and Guide Introduction to Economic Evaluation*. Virginia: Hoesch Marion Rousell Incorporation.
- Plumridge, R. J. (2001) 'Pharmacoeconomic Methods and Evaluation, Materi Lokakarya Farmakoekonomi'. Ikatan Sarjana Farmasi Indonesia.

- Probandari, A. (2007) 'Cost Effectiveness Analysis dalam Penentuan Kebijakan Kesehatan: Sekedar Konsep Atau Aplikatif?', *Jurnal Manajemen Pelayanan Kesehatan*, 10(03), p. 22237.
- Roehrborn, C. G. *et al.* (2011) 'Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial', *BJU international*, 107(6), pp. 946–954. doi: 10.1111/j.1464-410X.2011.10124.x.
- Speakman, M. *et al.* (2015) 'Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK', *BJU international*, 115(4), pp. 508–519. doi: 10.1111/bju.12745.
- Triplitt, C. L., Reasner, C. A. and Isley, W. L. (2019) 'Diabetes Mellitus', in *Pharmacotherapy: A Pathophysiologic Approach*. 10th edn. McGraw-Hill Companies, Inc, pp. 1333–1363.
- Trisna Y (2007) 'Aplikasi Farmakoekonomi', in *Majalah Medisina*. (3), pp. 24–27.
- Udeh, E. I. *et al.* (2016) 'A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model', *BMC cancer*, 16, p. 405. doi: 10.1186/s12885-016-2431-x.
- Venturini, F. and Johnson, K. A. (2002) 'Introduction to pharmacoeconomic principles and application in pharmacy practice', *Calif J Health Syst Pharm*, 14, pp. 6–14.
- Walker, A. *et al.* (2013) 'Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK', *BJU international*, 112(5), pp. 638–646. doi: 10.1111/j.1464-410X.2012.11659.x.
- Wei, J. T., Calhoun, E. and Jacobsen, S. J. (2005) 'Urologic diseases in America project: benign prostatic hyperplasia', *The Journal of Urology*, 173(4), pp. 1256–1261. doi: 10.1097/01.ju.0000155709.37840.fe.
- Zhang, A. Y. and Xu, X. (2018) 'Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature', *SAGE Open Nursing*, 4, p. 2377960818811773. doi: 10.1177/2377960818811773.